Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julien Adam

Showing results (151-160 of 152) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 152 results.
Nature Medicine|October 27, 2014
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapyAntonella Sistigu, Takahiro Yamazaki, Erika Vacchelli, et al.
The Journal of Pathology|March 5, 2020
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practicePaula I Gonzalez-Ericsson, Elisabeth S Stovgaard, Luz F Sua, et al.
Pageof 16

Showing results (151-160 of 152) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 152 results.
Nature Medicine|October 27, 2014
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapyAntonella Sistigu, Takahiro Yamazaki, Erika Vacchelli, et al.
The Journal of Pathology|March 5, 2020
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practicePaula I Gonzalez-Ericsson, Elisabeth S Stovgaard, Luz F Sua, et al.
Pageof 16